Brief profiles of these recently formed companies: Edimer Pharmaceuticals, EndoSphere Surgical, HanGenix and VenatorRx Pharmaceuticals.
1 Broadway, 8th Floor
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
